View More 2022, Presenter Profiles, Scientific Sessions

Presenter Profiles: Obesity Should Be the Primary Target of Treatment in Type 2 Diabetes


Estimated Read Time:

1 minute

Obesity Should Be the Primary Target of Treatment in Type 2 Diabetes

Saturday, June 4 at 1:45 p.m. CT
Great Hall A
Level 1, Ernest N. Morial Convention Center


Streaming: Live and On-Demand

Q&A with Ildiko Lingvay, MD, MPH, MSCS

Professor of Medicine
University of Texas Southwestern Medical Center

Ildiko Lingvay, MD, MPH, MSCS
Ildiko Lingvay, MD, MPH, MSCS

What is your presentation about?
Obesity is a major driver of the pathophysiology of type 2 diabetes and weight gain further promotes diabetes progression and is associated with worse glycemic control. Effectively and proactively addressing obesity in our patients with type 2 diabetes has benefits that extend well beyond glycemic control, improve the overall health of our patients and represent a holistic approach to complex disease. I propose we incorporate obesity treatment into the diabetes treatment algorithm and treatment goals.

What makes this topic important in 2022?
Obesity is a growing health condition that impacts health, social life, and society at many levels. It is imperative that stakeholders work together to coordinate multifaceted interventions intended to prevent, treat, and alleviate the consequences of obesity.

How did you become involved with this area of diabetes research or care?
Many of my patients struggle with complications from obesity. I wanted to be part of the solution and have the skills and knowledge to empower them to manage their condition.

What are you most looking forward to at the 82nd Scientific Sessions?
The networking with my peers, many of whom I have not seen in 3 years!